| Molecular Classification of the Inherited Hamartoma Polyposis Syndromes: Clearing the Muddied Waters The American Journal of Human Genetics, Volume 62, Issue 5, 1 May 1998, Pages 1020-1022 Charis Eng and HanLee Ji Full Text | PDF (52 kb) |
| Variant Manifestation of Cowden Disease in Japan: Hamartomatous Polyposis of the Digestive Tract with Mutation of the PTEN Gene The American Journal of Human Genetics, Volume 64, Issue 1, 1 January 1999, Pages 308-310 Keisuke Kurose, Tsutomu Araki, Tsuyoshi Matsunaka, Yasuharu Takada and Mitsuru Emi Full Text | PDF (231 kb) |
| Germline Mutations in BMPR1A/ALK3 Cause a Subset of Cases of Juvenile Polyposis Syndrome and of Cowden and Bannayan-Riley-Ruvalcaba Syndromes The American Journal of Human Genetics, Volume 69, Issue 4, 1 October 2001, Pages 704-711 Xiao-Ping Zhou, Kelly Woodford-Richens, Rainer Lehtonen, Keisuke Kurose, Micheala Aldred, Heather Hampel, Virpi Launonen, Sanno Virta, Robert Pilarski, Reijo Salovaara, Walter F. Bodmer, Beth A. Conrad, Malcolm Dunlop, Shirley V. Hodgson, Takeo Iwama, Heikki Järvinen, Ilmo Kellokumpu, J.C. Kim, Barbara Leggett, David Markie, Jukka-Pekka Mecklin, Kay Neale, Robin Phillips, Juan Piris, Paul Rozen, Richard S. Houlston, Lauri A. Aaltonen, Ian P.M. Tomlinson and Charis Eng Abstract Juvenile polyposis syndrome (JPS) is an inherited hamartomatous-polyposis syndrome with a risk for colon cancer. JPS is a clinical diagnosis by exclusion, and, before susceptibility genes were identified, JPS could easily be confused with other inherited hamartoma syndromes, such as Bannayan-Riley-Ruvalcaba syndrome (BRRS) and Cowden syndrome (CS). Germline mutations of () have been described in a variable number of probands with JPS. A series of familial and isolated European probands without mutations were analyzed for germline mutations in a member of the transforming growth-factor β–receptor superfamily, upstream from the SMAD pathway. Overall, 10 (38%) probands were found to have germline mutations, 8 of which resulted in truncated receptors and 2 of which resulted in missense alterations (C124R and C376Y). Almost all available component tumors from mutation-positive cases showed loss of heterozygosity (LOH) in the region, whereas those from mutation-negative cases did not. One proband with CS/CS-like phenotype was also found to have a germline missense mutation (A338D). Thus, germline mutations cause a significant proportion of cases of JPS and might define a small subset of cases of CS/BRRS with specific colonic phenotype. Abstract | Full Text | PDF (606 kb) |
Copyright © 2002 The American Society of Human Genetics. All rights reserved.
The American Journal of Human Genetics, Volume 70, Issue 4, 829-844, 1 April 2002
doi:10.1086/340026
Review Article
Kristin A. Waite1, 4 and Charis Eng1, 2, 3, 4,
, 
1 Human Cancer Genetics, The Ohio State University, Columbus
2 Clinical Cancer Genetics Programs, Comprehensive Cancer Center, The Ohio State University, Columbus
3 Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus
4 Division of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus
Address for correspondence and reprints: Dr. Charis Eng, Human Cancer Genetics Program, The Ohio State University, 420 West 12th Avenue, Suite 690TMRF, Columbus, OH 43210Germline mutations distributed across the PTEN tumor-suppressor gene have been found to result in a wide spectrum of phenotypic features. Originally shown to be a major susceptibility gene for both Cowden syndrome (CS), which is characterized by multiple hamartomas and an increased risk of breast, thyroid, and endometrial cancers, and Bannayan-Riley-Ruvalcaba syndrome, which is characterized by lipomatosis, macrocephaly, and speckled penis, the PTEN hamartoma tumor syndrome spectrum has broadened to include Proteus syndrome and Proteus-like syndromes. Exon 5, which encodes the core motif, is a hotspot for mutations likely due to the biology of the protein. PTEN is a major lipid 3-phosphatase, which signals down the PI3 kinase/AKT pro-apoptotic pathway. Furthermore, PTEN is a protein phosphatase, with the ability to dephosphorylate both serine and threonine residues. The protein-phosphatase activity has also been shown to regulate various cell-survival pathways, such as the mitogen-activated kinase (MAPK) pathway. Although it is well established that PTEN's lipid-phosphatase activity, via the PI3K/AKT pathway, mediates growth suppression, there is accumulating evidence that the protein-phosphatase/MAPK pathway is equally important in the mediation of growth arrest and other crucial cellular functions.